POSTER SESSION VI
Wednesday, March 2, 2011 — 1:00 PM - 4:00 PM
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
GYNECOLOGIC & OBSTETRICS PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
139
Is There a Need for Pre-Operative Evaluation in an Asymptomatic Patient Population Receiving a Supracervical Hysterectomy?
(1050)
A Gopinath, S Mandavilli, M Assaad, AC Steinberg - Hartford Hospital, CT
Vascular Pseudoinvasion in Laparoscopic Hysterectomies: Intraoperative Effect or Pathology Grossing Artifact?
(1039)
L Feeley, AM Mulligan, S James, A Krizova, B Clarke - St Michaels Hospital, Toronto, Canada; UHN, Toronto, Canada; University of Toronto, ON, Canada
Utility of PAX2 as a Marker for Diagnosis of Endometrial Intraepithelial Neoplasia (EIN).
(1120)
CM Quick, AR Laury, NM Monte, GL Mutter - Brigham and Women's Hospital, Boston, MA
Expression of S100P in Benign Endometrium and Endometrial Adenocarcinoma.
(1041)
W Feng, Q Shen, RE Brown, X Duan - University of Texas Medical School, Houston
Absence of TTF-1 in Benign Endometrium and Simple Hyperplasia Is Associated with Progression to Cancer.
(1138)
PS Sullivan, E Maresh, L Goodglick, M Wadehra, O Dorigo - UCLA David Geffen School of Medicine, Los Angeles, CA
Factors Predicting Response to Progestin Treatment for Complex Atypical Hyperplasia/Well Differentiated Endometrial Carcinoma in Premenopausal Patients.
(997)
C Aoyama, K Penner, N Ostrzega, J Rao, C Walsh, O Dorigo, I Cass, B Balzer, C Holschneider - Olive View-UCLA Medical Center, Sylmar, CA; UCLA Medical Center, Los Angeles, CA; Cedar-Sinai Medical Center, Los Angeles, CA
Progesterone Receptors A and B, pAkt, and p4EBP1 Expression Patterns in Grade 1 Endometrial Adenocarcinoma(G1EAC) and Complex Atypical Hyperplasia(CAH) and Prediction of Response to Progestin Therapy.
(1116)
KR Penner, M Wadehra, AA Steinhardt, CP Hogue, IE Cass, CS Walsh, CH Holschneider, J Braun, O Dorigo - UCLA Medical Center, Los Angeles, CA; Olive View-UCLA Medical Center, Los Angeles, CA; Cedars Sinai Medical Center, Los Angeles, CA
Preinvasive Stage in the Endometrium: Relation and Role of Clonal Expansion and PTEN.
(1002)
H Baloglu - GATA Haydarpasa Training Hospital, Istanbul, Turkey
Temporal Relationships between Tamoxifen Use and Endometrial Malignancies.
(1026)
D DeLair, S Ferguson, R Soslow, K Garg - Memorial Sloan-Kettering Cancer Center, New York, NY
Size of Endometrial Adenocarcinoma and Non-Cancerous Tissue in Biopsy Have Predictive Value for Finding Endometrial Adenocarcinoma in Hysterectomy.
(1104)
K Mittal, S Sasturkar, A Salem - NYU School of Medicine, New York, NY
Pathologic Characteristics of Endometrial Carcinoma in Women 40 Years of Age and Younger.
(1143)
C Uram-Tuculescu, E Dragoescu - Virginia Commonwealth University Health System, Richmond
Clinicopathological Characterization of Endometrial Carcinomas Arising in Elderly Women Aged over 70 Years.
(1154)
M Yasuda, S Hori, T Katoh, M Shimizu, K Fujiwara, N Ogane, Y Kameda, H Nakayama - Saitama Medical University International Medical Center, Hidaka, Japan; Kanagawa Cancer Center, Yokohama, Japan
Low Grade, Low Stage Endometrioid Adenocarcinoma of the Endometrium: Clinical Implications of the Pattern of Myoinvasion.
(1119)
CM Quick, T May, NS Horowitz, MR Nucci - Brigham and Women's Hospital, Boston, MA
Mucinous Adenocarcinoma of the Endometrium Confers Increased Risk of Lymph Node Metastases.
(1107)
F Musa, B Adams, K Holcomb, E Pirog - Weill Cornell Medical College, New York, NY
Immunohistochemical Panel of p16, p63 and Ki-67 Is Useful in Distinguishing Mucinous Adenocarcinomas of Endometrium (MUC-ADs) from Microglandular Hyperplasia (MGH) of Endocervix.
(1109)
A Nayak, NJ Morgenstern, TA Bhuiya - Albert Einstein College of Medicine at Long Island Jewish Medical Center, New Hyde Park, NY
K-ras Mutations in Endometrial Carcinoma of Uterus . Molecular and Morphological Correlation.
(1150)
J Xiong, M He, CL Jackson, V Breese, CJ Sung, MM Steinhoff, MR Quddus, WDD Lawrence - Women & Infants Hospital, Providence, RI; Rhode Island Hospital, Providence
Clinicopathologic Features of Sporadic Endometrial Carcinomas with MLH1 Promoter Hypermethylation: A Study of 54 Cases.
(1103)
AM Mills, RK Pai, S Liou, TA Longacre - Stanford University, CA
Poor Interobserver Reproducibility in the Diagnosis of High-Grade Endometrial Carcinoma.
(1049)
CB Gilks, E Oliva, R Soslow - Vancouver General Hospital and BC Children's and Women's Hospital, BC, Canada; Massachusetts General Hospital, Boston; Memorial Sloan Kettering Cancer Center, New York, NY
Presence of Tumor Necrosis in Endometrial Biopsy Predicts Advanced Stage of Endometrial Adenocarcinoma.
(1125)
RS Saad, M Mashhour, A Shehata, N Ismiil, S Nofech-Mozes, V Dube, Z Ghorab, MA Khalifa - Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Histologic Patterns of Recurrent Endometrial Carcinoma.
(1016)
M Cesari, DA Levine, S Wethington, N Olvera, DJ Chiappetta, K Garg, RA Soslow - Memorial Sloan-Kettering Cancer Center, New York, NY
Impact of DNA Mismatch Repair (MMR) in Endometrial Cancer in a Single Reference Center in Mexico.
(1117)
D Perez Montiel, D Cantu de Leon, A Gamboa Dominguez, J Chanona Vilchis, C Cavazos - Instituto Nacional de Cancerologia, Mexicio city, Mexico; Instituto Nacional de Cancerologia, Mexico city, Mexico; Instituto Nacional de la Nutricion, Mexico city, Mexico
Lynch Syndrome Screening Should Be Considered for All Patients with Newly Diagnosed Endometrial Cancer.
(1101)
AM Mills, S Liou, JM Ford, JS Berek, RK Pai, TA Longacre - Stanford University, CA
MLH1-Deficient Ovarian and Endometrial Carcinomas Most Often Result from Epigenetic Silencing of MLH1 by Promoter Hypermethylation and Do Not Harbor BRAF V600E Mutations: Implications for Identifying Patients with Lynch Syndrome (LS).
(1069)
J Kitayama, TA Longacre, S Liou, L Ma, D Arber, RK Pai - Stanford University, CA
Absence of V600E B-RAF Mutation in MLH1-Negative Endometrial Carcinoma.
(1108)
E Musulen, AM Munoz-Marmol, C Sanz, C Carrato, JL Mate, A Ariza - Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Synchronous Versus Metastatic Gynecological Cancers: A Comparative Mutational Profiling Study.
(1067)
S Khelifa, SD Finkelstein, P Hui - Yale University, New Haven, CT; RedPath Integrated Pathology, Pittsburgh, PA
mTOR Expression Is Not Associated with FIGO Grade in Uterine Endometrioid Carcinoma.
(1017)
JSY Chan, LH Ellenson - NYP Weill Cornell Medical Center, New York City, NY
Dedifferentiated Carcinoma of the Endometrium and the Ovary: A Molecular Study of 8 Cases.
(999)
A Azueta, S Gatius, A Velasco, M Santacana, J Pallares, B Clarke, E Oliva, X Matias-Guiu - Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Spain; Massachusetts General Hospital, Boston; Toronto General Hospital, Canada
Differentially Expressed Genes in Early Stages Uterine Serous Carcinomas in Comparison to G3 and G1 Endometrioid Adenocarcinoma.
(1139)
S Syriac, D Wang, J Kesterson, K Odunsi, S Lele, S Liu, P Mhawech-Fauceglia - Roswell Park Cancer Institute, Buffalo, NY
Her2-Neu Over-Expression in Serous and Clear Cell Endometrial Carcinoma.
(1137)
RG Stovel, RS Saad, N Ismiil, Z Ghorab, V Dube, MA Khalifa, S Nofech-Mozes - Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Expression of Tissue Factor and Heparanase in Endometrial Clear Cell Carcinomas: Clinicopathologic Significance and a Possible Role for Tissue Factor in Thromboembolic Events.
(1036)
O Fadare, I Renshaw, SX Liang - Vanderbilt University, Nashville; Vanguard Pathology, Austin; Long Island Jewish Medical Ctr, New Hyde Park
Tumor Associated Macrophages and Correlation with Prognostic Factors in Endometrial Adenocarcinomas.
(1005)
SL Bohman, EC Dun, EA Reynolds, J Yi, F Wieser, RN Taylor, K Hanley - Emory University, Atlanta, GA
Array Comparative Genomic Hybridization and Fluorescence In Situ Hybridization Analysis of Endometrial Carcinoma Specimens.
(1145)
JS Voss, BR Kipp, LM Peterson, F Medeiros, MB Campion, E Pestova, KB Jacobson, MS Legator, AC Clayton, KC Halling - Mayo Clinic, Rochester, MN; Abbott Molecular Inc., Des Plaines, IL
The Expression and Value of Aldolase in Endometrial Cancer and the Role of Clotrimazole in Endometrial Cancer Cell Viability and Morphology.
(1131)
S Shroff, D Wang, J Kesterson, S Liu, K Odunsi, P Mhawech-Fauceglia - University at Buffalo, SUNY, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
Stem Cell Marker Expression in Endometrial Carcinoma.
(1140)
J Tarragona, M Santacana, J Valls, E Oliva, J Palacios, X Matias-Guiu - Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Massachusetts General Hospital, Boston
Loss of PTEN Expression but Intact Expression of Mismatch Repair Proteins (MLH-1 and MSH-2) in Atypical Polypoid Adenomyomas of the Uterus.
(1024)
M Cruise, T Longacre, E Stelow - University of Virginia, Charlottesville; Stanford, Stanford, CA
Correlation of the Volume of Carcinomatous Component with the Clinical Stage and Nodal Metastasis in Uterine Carcinosarcoma.
(987)
Y Ahmed, H Nasser, M Al-Hajeili, T Kuntzman, B Albashiti, R Ali-Fehmi, P Mazzara, L Fathallah - St John Providence Hospital and Medical Center, Detroit, MI; William Beaumont Hospital, Royal Oak, MI; Wayne State University, Detroit, MI
Molecular Genetics of Uterine Malignant Mixed Mullerian Tumor.
(1152)
AY-P Yang, D Lu, Y-F Liu, LH Ellenson - Weill Medical College of Cornell University, New York, NY
Molecular Alterations in Endometrial Carcinosarcomas (ECS).
(1004)
M Biscuola, K Van De Vijver, MA Castilla, L Romero-Perez, MA Lopez-Garcia, J Palacios, E Oliva - Hospital Universitario Virgen del Rocio-IBIS (Instituto de Biomedicina de Sevilla), Seville, Spain; Massachusetts General Hospital, Boston
Micro-RNA Signature of the Epithelial-Mesenchymal Transition in Endometrial Carcinosarcoma.
(1015)
MA Castilla, G Moreno-Bueno, L Romero-Perez, K Van De Vijver, M Biscuola, MA Lopez-Garcia, J Prat, X Matias-Guiu, A Cano, E Oliva, J Palacios - Hospital Universitario Virgen del Rocio-IBIS, Sevilla, Spain; Instituto de Investigaciones Biomedicas "Alberto Sols" (CSIC-UAM), IdiPAZ (Instituto de Investigacion La Paz), Madrid, Spain; Massachusetts General Hospital, Boston; Hospital San Pau, Barcelona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain
Reverse Phase Protein Lysate Array (RPPA) Identifies Differential Protein Expression in Uterine Carcinosarcoma.
(1034)
ED Euscher, C Wei, BR Russell - MD Anderson Cancer Center, Houston, TX
Correlation of HB-EGF Paracrine and Autocrine with Advanced Stages of Malignant Mixed Mullerian Tumor.
(1158)
L Zhang, D Shimizu, SA Honda, J Killeen, I Pagano, M Carbone - University of Hawaii, Honolulu
microRNAs and Their Target Gene Networks in Uterine Leiomyomas.
(1147)
J-J Wei, Z Liu, J Zavadil, P Soteropoulos, H Ye - Northwestern University, Chicago, IL; UMDNJ-New Jersey Medical School, Newark, NJ; New York University, NY
Uterine Leiomyosarcoma with an Adipocytic Differentiation (Lipoleiomyosarcoma): A Clinicopathologic Study of Seven Cases.
(1100)
Y Mikami, MR Nucci, Y Yuba, S Minamiguchi, S Sawada, Y Uemura - Kyoto University Hospital, Japan; Brigham and Women's Hospital, Boston, MA; Kitano Hospital, Osaka, Japan; Kyoto Medical Center, Japan; Nagahama City Hospital, Shiga, Japan; Kansai Medical School, Hirakata Hospital, Osaka, Japan
Old Versus New FIGO Staging Systems in Predicting Overall Survival in Patients with Uterine Leiomyosarcoma: A Study of 86 Cases.
(1085)
D Lim, W-L Wang, C-H Lee, T Dodge, B Gilks, E Oliva - National University Health System, Singapore, Singapore; M.D Anderson Cancer Center, Houston, TX; Vancouver General Hospital, BC, Canada; Massachusetts General Hospital, Boston
Dysregulation of the Phosphatidylinositol 3' Kinase-Akt-Mammalian Target of Rapamycin (P13K-Akt-mTOR) Pathway in Smooth Muscle Tumors of the Uterus: Clinicopathologic Implications.
(1037)
O Fadare, I Renshaw, SJ Olson, SX Liang - Vanderbilt University, Nashville, TN; Vanguard Pathology, Austin, TX; Long Island Jewish Medical Center, New Hyde Park, NY
Molecular and Genetic Characterization of Diagnostically Challenging Uterine Smooth Muscle Neoplasms.
(1084)
B Liegl, K Flicker, F Tavassoli, M Speicher, F Moinfar - Medical University of Graz, Austria; Yale University School of Medicine, New Haven, CT
Comparative Proteomic Analysis of Uterine Leiomyomas and Leiomyosarcomas.
(1141)
GA Trucco, BL Hood, TP Conrads, JM Jones-Laughner, M Sun, MW Jones - UMPC/Magee Womens Hospital/University of Pittsburgh, PA; University of Pittsburgh Cancer Institute/Magee Womens Research Institute, PA
Diagnostic Utility of JAZF1/JJAZ1 Fusion Gene in Endometrial Stromal Sarcoma of the Uterus.
(1080)
S-R Lee, J Choi, HK Kim, Y Lee, K-R Kim - University of Ulsan College of Medicine, Seoul, Korea
Prognostic Indicators of Uterine Adenosarcoma Based on 2010 AJCC Staging Criteria . A Clinicopathologic Study of 39 Cases over 20 Years.
(1018)
P-Y Chen, JJ Ou, CJJ Sung, MRR Quddus, WDD Lawrence, MM Steinhoff - Warrent Alpert Medical School of Brown University & Women & Infants Hospital, Providence, RI; Changhua Christian Hospital, Taiwan
Immunohistochemical and Mutational Analysis of FOXL2 in Uterine Tumors Resembling Ovarian Sex-Cord Tumors.
(1021)
S Chiang, B Gilks, DG Huntsman, E Oliva - Massachusetts General Hospital, Boston; BC Cancer Agency, Vancouver, BC, Canada
Class III Beta-Tubulin Expression in Endometrial Tumors.
(1093)
M Lomme, N Kawar, D Dizon, D Lawrence - Women & Infants Hospital of Rhode Island, Providence, RI
Detection of ALK Gene Rearrangements Aids in the Diagnosis of Inflammatory Myofibroblastic Tumor of the Uterus.
(1042)
NE Fuehrer, DA Bell - Mayo Clinic, Rochester, MN
button next to any title to add to Itinerary Planner...
Add
